
Dr. Roué on Interest With TG-1701 in Ibrutinib-Resistant MCL Models
Gaël Roué, PhD, discusses interest regarding the novel irreversible inhibitor TG-1701 in models of ibrutinib (Imbruvica)-resistant mantle cell lymphoma.
Gaël Roué, PhD, senior scientist at Josep Carreras Leukaemia Research Institute, discusses interest regarding the novel irreversible inhibitor TG-1701 in models of ibrutinib (Imbruvica)-resistant mantle cell lymphoma (MCL).
A study presented at the
Another point of interest is that when investigators compared the second-generation molecule with the first-in-class inhibitor, ibrutinib, they found that some activity was retained in cases of resistance to ibrutinib, concludes Roué.


































